Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Bausch Health closes Wuhan Shibo acquisition

By The Northwire Desk — AI Analysis Dec 01, 2025 · 16:22 BHC · 9.88 Bausch Health Companies Inc
BHC · Price

Executive Summary

  • Bausch Health’s aesthetics division, Solta Medical, completed the acquisition of Wuhan Shibo Zhenmei Technology Co. Ltd., the longtime Chinese distribution partner for its Thermage FLX and other aesthetic devices.
  • Effective December 1 2025, Shibo becomes a wholly‑owned subsidiary of Solta Medical in China, giving Solta direct control over distribution and expanding its market presence.
  • The deal is positioned to accelerate revenue growth and market share in the rapidly expanding Chinese aesthetics market.

Key Details

  • Acquirer: Solta Medical, the global aesthetic business of Bausch Health Companies Inc.
  • Target: Wuhan Shibo Zhenmei Technology Co. Ltd., operating as the “Shibo Group,” a private distributor of medical beauty products based in Wuhan, Hubei, China.
  • Transaction Structure: 100 % equity acquisition; Shibo becomes a wholly‑owned subsidiary of Solta Medical.
  • Effective Date: December 1 2025.
  • Products Affected: Full responsibility for distribution of Solta’s Thermage FLX and other aesthetic devices in China.
  • Strategic Rationale: Leverages an existing, decade‑long distribution network and local market knowledge to instantly access a large customer base, improve service speed, and capture growing demand for aesthetics treatments.
  • Management Comments:
  • Thomas J. Appio (CEO, Bausch Health) highlighted expanded geographic reach, market scale, and anticipated revenue growth.
  • Jiny Kim (SVP, Solta Medical) noted the integration will enhance innovation and customer service.
  • Belinda Bao (VP & GM, Solta China) emphasized stronger positioning as a growth driver for Bausch Health in China.

Notable Quotes

  • “This acquisition expands Solta Medical's geographical reach and market scale in China… to drive future revenue and market share growth.” – Thomas J. Appio, CEO, Bausch Health
  • “Integrating their team into Solta Medical allows us to build on that trust and deliver even greater value‑accelerating innovation by being closer to our customers.” – Jiny Kim, Senior Vice‑President, Solta Medical

Materiality Assessment: Material – Positive (the acquisition is expected to materially enhance Solta Medical’s market position and revenue potential in China).

Read the original news release →

More from Bausch Health Companies Inc

Jun 09, 2026 · 08:00

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

Regulatory May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other Feb 23, 2026 · 17:59

Bausch Health launches Clear + Brilliant in Canada

Regulatory Feb 23, 2026 · 08:00

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

Production / Operations